Dr. Elizabeth Plimack on Nivolumab in Kidney Cancer

Elizabeth Plimack, MD
Published: Friday, Jul 15, 2016

 
Elizabeth Plimack, MD, Director of Genitourinary Clinical Research, Associate Professor, department of hematology/oncology, Fox Chase Cancer Center, discusses the role of nivolumab in kidney cancer.
 
We now have long-term follow-up data from patients that have been on nivolumab for four to five years, says Plimack. About one-third of patients are still alive at four years.
 
This long-term benefit occurred in patients regardless of their initial response to therapy and risk group.
 
Biomarker development is needed, and as well as research regarding adverse events and combination possibilities. A lot can still be learned regarding how nivolumab should be used in kidney cancer, says Plimack.
 
SELECTED
LANGUAGE
 
Elizabeth Plimack, MD, Director of Genitourinary Clinical Research, Associate Professor, department of hematology/oncology, Fox Chase Cancer Center, discusses the role of nivolumab in kidney cancer.
 
We now have long-term follow-up data from patients that have been on nivolumab for four to five years, says Plimack. About one-third of patients are still alive at four years.
 
This long-term benefit occurred in patients regardless of their initial response to therapy and risk group.
 
Biomarker development is needed, and as well as research regarding adverse events and combination possibilities. A lot can still be learned regarding how nivolumab should be used in kidney cancer, says Plimack.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x